Ten23 health expands newly acquired sterile drug product manufacturing site

The expansion will provide additional cold storage and visual inspection capacity, as well as cleanrooms for device assembly and secondary packaging

To enable further growth of its existing production capacity, the CDMO has chosen to focus initially on expanding supporting areas in an adjacent building.

Specifically, an extra 1000 m2 of cleanroom space has been ear-marked for visual inspection and cold storage, as well as additional services including supporting device assembly operations, labelling and secondary packaging.

Currently, the swissfillion site provides sterile manufacturing of prefilled syringes, vials and cartridges for clinical trial and market supplies.

Swissfillion's expertise in sterile drug product manufacturing for complex pharmaceuticals combined with ten23 health’s experience in developing and manufacturing injectable treatments provides an integrated offering for sterile drug product development and manufacturing of biologics, challenging molecules and dosage forms.

According to ten23 health CEO Hanns-Christian Mahler, expanded drug development pipelines incorporating more complex, large-molecule products and therapies requiring specific expertise for both development and sterile production are driving a demand for sterile fill/finish services.

Speaking about the expansion, he said: "It is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients."

The size of the investment was not disclosed.